Skip to content
DraconiticResearch
Search Sources API
194,161 studies31 sourcesUpdated 8 min ago
Peer-reviewedCC BY 4.0Cancers

Cutaneous T-Cell Lymphoma and Cutaneous CAR-T Lymphoma in Patients with Other Malignancies

  • Caroline S. Myers1
  • Elise A. Olsen2
  • Christina Cruz1
  • Ellen J. Kim1
  • Tatyana Feldman3
  • Alejandro Gru4
  • Larisa J. Geskin4
4 affiliations
  1. 1Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  2. 2Duke University Medical Center, Durham, NC 27710, USA
  3. 3Division of Lymphoma, John Theurer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA
  4. 4Department of Dermatology, Columbia University, New York, NY 10032, USA
Open at sourceDOICite

Abstract

Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin-homing T cells associated with increased risk of second malignancies. CAR-T lymphoma is a mature T-cell malignancy arising in cancer patients treated with chimeric antigen receptor T-cell (CAR-T) therapy. Because of its frequent cutaneous involvement, CAR-T lymphoma can mimic CTCL, which in turn can resemble cutaneous sequelae of oncologic therapies. Careful evaluation of these entities in cancer patients is therefore essential, yet little guidance exists regarding optimal methods of screening, diagnosis, and treatment. Clinicians managing CTCL in cancer patients should consider how oncologic treatment toxicities may overlap with CTCL treatment toxicities or affect patients’ risk for other skin cancers. Where possible, immune-boosting or at least immune-preserving treatments are preferred, with immune checkpoint inhibition emerging as an important option in selected patients. Patients with a history of CAR-T therapy and new, persistent skin findings should undergo careful work-up with molecular screening for lymphoproliferative processes. Presence of a CAR in lesional tissue can be suggestive but is not diagnostic of a CAR-T-associated malignancy. Treatment for any patient with a cutaneous T-cell or CAR-T lymphoma and a second cancer should be an interdisciplinary effort tailored to the patient’s specific medical history and molecular profile. Further research is needed to establish better evidence-based guidelines for treatment of these patient populations.

Related

  1. Outcomes of brentuximab vedotin in cutaneous T-cell lymphoma: A Middle Eastern real-world study
    Ahmad Alsarraf, Hashem Boalbanat, Jihan Rajy +3
    JAAD internationalPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Clonal expansion of CAR-T cells harboring lentivector integration in the PLAAT4 gene following anti-CD19 CAR T-cell therapy in a context of cutaneous T-cell lymphoma
    Vincent Guiraud, Clotilde Bravetti, Amélie Guihot +13
    HaematologicaPeer-reviewedCC BY-NC 4.0Full textImmunologyOncologyHAL
  3. Follicular Lymphoma Involving the Supraglottic Larynx in a Patient with Recurrent Cutaneous B-cell Lymphoproliferative Lesions: A Case Report
    Ryohei Asai, Hiroumi Matsuzaki, Shimon Otake +2
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  4. Cronkhite-Canada Syndrome Associated with Primary Cutaneous Peripheral T-cell Lymphoma and Membranous Nephropathy: A Case Report
    Kohei Kiso, Yusuke Shimoyama, Saki Okuda-Hiwatashi +11
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  5. Intravascular large B-cell lymphoma (IVLBCL) presenting with exclusive cutaneous involvement, no B-symptoms and negative PET-CT: A Case Study.
    Juliana Gabzdilova, Atila David Homolya, Stefan Raffac +5
    Leukemia research reportsPeer-reviewedCC BYFull textNeurologyEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{myers2026cutaneous,
  title = {{Cutaneous T-Cell Lymphoma and Cutaneous CAR-T Lymphoma in Patients with Other Malignancies}},
  author = {Caroline S. Myers and Elise A. Olsen and Christina Cruz and Ellen J. Kim and Tatyana Feldman and Alejandro Gru and Larisa J. Geskin},
  journal = {Cancers},
  year = {2026},
  month = nov,
  doi = {10.3390/cancers18213527},
  url = {https://www.mdpi.com/2072-6694/18/21/3527},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Cutaneous T-Cell Lymphoma and Cutaneous CAR-T Lymphoma in Patients with Other Malignancies
AU  - Caroline S. Myers
AU  - Elise A. Olsen
AU  - Christina Cruz
AU  - Ellen J. Kim
AU  - Tatyana Feldman
AU  - Alejandro Gru
AU  - Larisa J. Geskin
PY  - 2026
DA  - 2026/11/03
JO  - Cancers
DO  - 10.3390/cancers18213527
UR  - https://www.mdpi.com/2072-6694/18/21/3527
AB  - Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin-homing T cells associated with increased risk of second malignancies. CAR-T lymphoma is a mature T-cell malignancy arising in cancer patients treated with chimeric antigen receptor T-cell (CAR-T) therapy. Because of its frequent cutaneous involvement, CAR-T lymphoma can mimic CTCL, which in turn can resemble cutaneous sequelae of oncologic therapies. Careful evaluation of these entities in cancer patients is therefore essential, yet little guidance exists regarding optimal methods of screening, diagnosis, and treatment. Clinicians managing CTCL in cancer patients should consider how oncologic treatment toxicities may overlap with CTCL treatment toxicities or affect patients’ risk for other skin cancers. Where possible, immune-boosting or at least immune-preserving treatments are preferred, with immune checkpoint inhibition emerging as an important option in selected patients. Patients with a history of CAR-T therapy and new, persistent skin findings should undergo careful work-up with molecular screening for lymphoproliferative processes. Presence of a CAR in lesional tissue can be suggestive but is not diagnostic of a CAR-T-associated malignancy. Treatment for any patient with a cutaneous T-cell or CAR-T lymphoma and a second cancer should be an interdisciplinary effort tailored to the patient’s specific medical history and molecular profile. Further research is needed to establish better evidence-based guidelines for treatment of these patient populations.
SN  - 2072-6694
ER  -